This article is more than 5 years old. Information may no longer be current.
AACE/ACE app offers clinical guidance for management of type 2 diabetes
Click Here to Manage Email Alerts
ORLANDO, Fla. —The American Association of Clinical Endocrinologists and the American College of Endocrinology announced the worldwide availability of an in-depth, point-of-care app designed to offer clinical practice guidance for the management of type 2 diabetes.
The free app, based on the AACE/ACE comprehensive diabetes management algorithm, includes recommendations for evidence-based approaches to treatment based on a patient’s individual risks and complications.
The app was first launched in the U.S in February and is intended for both health care providers and patients; it is now available worldwide.
“There are many comorbid conditions associated with diabetes, and this app is based on the model that glycemic control is not the whole story,” Jeffrey R. Garber, MD, FACP, FACE, professor of medicine at Harvard Medical School and member of the AACE/ACE Task Force that authored the algorithm on which the app is based, said during a press conference at the AACE Annual Scientific and Clinical Congress. “Obesity and hypertension are part of properly managing diabetes.”
Jeffrey R. Garber
Using the example of an “entry” HbA1c of 7%, Garber demonstrated how the app tailors recommendations according to a patient’s specific risks and goals, by ranking recommended agents by monotherapy, dual therapy and triple therapy, and further breaking down the rationale behind each recommended agent. The app also includes a built-in insulin titration mechanism based on patient goals.
The app includes the algorithm executive summary along with informational buttons that help guide the user through an action-driven treatment pathway.
“It’s a fairly simple app in terms of functionality, but it links to a robust body of information that’s in very detailed narrative guidelines, the key points of which we incorporated in this,” Garber, a member of the Endocrine Today Editorial Board, said.
“We think [the app is] a great opener for conversation, informing the discussion between the patient and doctor,” Garber said.
To download the app, visit aace.com/apps/type2diabetes. – by Regina Schaffer
Reference:
Garber JR. Presented at: AACE Annual Scientific and Clinical Congress; May 25-29, 2016; Orlando, Fla.
Disclosure: AstraZeneca provided a grant for development of the app, but had no role in its design. Garber reports no relevant financial disclosures.